The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment

Exclusion Criteria

• •History of peripheral neuropathy attributed to any cause other than chemotherapy.
• •Patients receiving any concurrent agents known to cause peripheral neuropathy within 30 days of Randomization.
• •Current use of other therapy (ies), including "alternative" therapies, for treatment of peripheral neuropathy within 30 days of Randomization (with the exception of protocol allowed concurrent medications).
• •Patients who used controlled release opioids within seven days of baseline period or who expect to use controlled release opioids at any time from baseline to end of study.
• •Patients with abnormal kidney function.
• •Patients with bone metastases.
• •Patients scheduled for treatment for their cancer with chemotherapy or radiotherapy between screening and the end of study visit.
• •Current use of lidocaine and other types of antiarrhythmic drugs within 30 days of Randomization.
• •Current use of scopolamine and acetylcholinesterase-inhibiting drugs such as physostigmine within 30 days of Randomization.
• •Current cause of Chemotherapy Induced Neuropathic Pain attributed to Velcade (Bortezomib) or vinca alkaloids or analogues such as vincristine, vinblasine, vinorelbine and vindesine.
• •Current use of tricyclic antidepressant medication, anticonvulsants and monoamine oxidase inhibitors.
• •Patients with current uncontrolled asthma or lung disease.
• •Patients with significant heart disease.
• •Use of an investigational agent within 30 days prior to screening or is scheduled to receive an investigational drug other than TTX during the course of the study.
• •Females who are pregnant or nursing